Advertisement
Singapore markets closed
  • Straits Times Index

    3,489.57
    +1.66 (+0.05%)
     
  • S&P 500

    5,605.60
    -61.60 (-1.09%)
     
  • Dow

    41,103.71
    +149.23 (+0.36%)
     
  • Nasdaq

    18,096.43
    -412.91 (-2.23%)
     
  • Bitcoin USD

    65,021.44
    +1,423.08 (+2.24%)
     
  • CMC Crypto 200

    1,347.86
    +5.53 (+0.41%)
     
  • FTSE 100

    8,201.53
    +36.63 (+0.45%)
     
  • Gold

    2,474.80
    +7.00 (+0.28%)
     
  • Crude Oil

    82.23
    +1.47 (+1.82%)
     
  • 10-Yr Bond

    4.1940
    +0.0270 (+0.65%)
     
  • Nikkei

    41,097.69
    -177.39 (-0.43%)
     
  • Hang Seng

    17,739.41
    +11.43 (+0.06%)
     
  • FTSE Bursa Malaysia

    1,633.54
    +7.58 (+0.47%)
     
  • Jakarta Composite Index

    7,224.22
    -0.08 (-0.00%)
     
  • PSE Index

    6,687.71
    +20.62 (+0.31%)
     

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., August 28, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20230828696222/en/

Contacts

Media Contact
Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokegroup.com
media@sprucebio.com

Investors
Samir Gharib
President and CFO
Spruce Biosciences
investors@sprucebio.com